44.200.137.63
dgid:
enl:
npi:0
Journal Scan
Oncology

Acalabrutinib Shows Promise in Relapsed/Refractory Mantle Cell Lymphoma

Posted on

The Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) was recently approved in the United States for adults with relapsed or refractory mantle cell lymphoma (MCL). In ACE-LY-004, a single-arm, open-label phase 2 trial, 124 patients received oral acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity. At median follow-up of 15 months, the overall response rate was 81%, which included a complete response rate of 40%. Although median duration of progression-free survival and overall survival were not reached at data cut-off, the 12-month rates were 67% (95% CI, 58%-75%) and 87% (95% CI, 79%-92%), respectively. Median duration of treatment was 13.8 months. The most common grade 3 or higher adverse events were neutropenia (10%), anemia (9%), and pneumonia (5%).

Read more here.

Reference

Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-